X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (30) 30
humans (29) 29
index medicus (28) 28
male (26) 26
middle aged (24) 24
aged (23) 23
female (21) 21
adult (17) 17
chemotherapy (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
treatment outcome (12) 12
aged, 80 and over (11) 11
cetuximab (10) 10
antineoplastic agents - therapeutic use (9) 9
cancer (9) 9
adenocarcinoma - drug therapy (8) 8
colorectal neoplasms - drug therapy (8) 8
therapy (8) 8
antibodies, monoclonal, humanized (7) 7
carcinoma (7) 7
colorectal cancer (7) 7
deoxycytidine - administration & dosage (7) 7
deoxycytidine - analogs & derivatives (7) 7
metastasis (7) 7
mutation (7) 7
prognosis (7) 7
retrospective studies (7) 7
capecitabine (6) 6
cisplatin (6) 6
fluorouracil - administration & dosage (6) 6
receptor, epidermal growth factor - antagonists & inhibitors (6) 6
tumors (6) 6
adenocarcinoma (5) 5
adenocarcinoma - pathology (5) 5
antibodies, monoclonal - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
class i phosphatidylinositol 3-kinases (5) 5
fluorouracil (5) 5
fluorouracil - analogs & derivatives (5) 5
neoplasm metastasis (5) 5
neoplasm staging (5) 5
pancreatic cancer (5) 5
pancreatic neoplasms - drug therapy (5) 5
proto-oncogene proteins b-raf - genetics (5) 5
survival analysis (5) 5
5-fluorouracil (4) 4
colorectal neoplasms - pathology (4) 4
disease-free survival (4) 4
gene expression regulation, neoplastic (4) 4
genetic aspects (4) 4
growth-factor receptor (4) 4
medicine (4) 4
medicine & public health (4) 4
oxaliplatin (4) 4
pancreatic neoplasms - pathology (4) 4
phosphatidylinositol 3-kinases - genetics (4) 4
proto-oncogene proteins p21 (4) 4
review (4) 4
time factors (4) 4
1st-line treatment (3) 3
analysis (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
biomarkers, tumor - genetics (3) 3
cancer therapies (3) 3
chemotherapy, adjuvant (3) 3
cisplatin - administration & dosage (3) 3
clinical trials (3) 3
colorectal neoplasms - genetics (3) 3
curative resection (3) 3
digestive system diseases (3) 3
disease progression (3) 3
drug resistance, neoplasm - genetics (3) 3
drug therapy (3) 3
efficacy (3) 3
egfr (3) 3
europe (3) 3
gastroenterology & hepatology (3) 3
gemcitabine (3) 3
gene copy number (3) 3
genes, ras (3) 3
health aspects (3) 3
irinotecan (3) 3
k-ras (3) 3
kras (3) 3
medical and health sciences (3) 3
medical prognosis (3) 3
medical research (3) 3
medicin (3) 3
medicin och hälsovetenskap (3) 3
metastatic colorectal-cancer (3) 3
pancreatic neoplasms - mortality (3) 3
patients (3) 3
proto-oncogene proteins - genetics (3) 3
quality of life (3) 3
ras proteins - genetics (3) 3
research (3) 3
stomach neoplasms - drug therapy (3) 3
stomach neoplasms - pathology (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 8, pp. 753 - 762
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2008, Volume 26, Issue 35, pp. 5705 - 5712
Purpose Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately... 
GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | PROGNOSTIC-FACTOR | MUTATION STATUS | THERAPY | ONCOLOGY | MISMATCH-REPAIR | OPEN-LABEL | KRAS | GENE COPY NUMBER | CHEMOTHERAPY | Niacinamide - analogs & derivatives | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Phenylurea Compounds | Patient Selection | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Benzenesulfonates - pharmacology | Neoplasm Metastasis | Time Factors | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Cetuximab | Cell Survival - drug effects | Colorectal Neoplasms - enzymology | Proto-Oncogene Proteins - genetics | Treatment Outcome | Switzerland | HT29 Cells | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Italy | Aged | Biomarkers, Tumor - genetics | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Mutation | Colorectal Neoplasms - pathology | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 2, pp. 132 - 138
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2009, Volume 4, Issue 10, pp. e7287 - e7287
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2007, Volume 25, Issue 16, pp. 2212 - 2217
Journal Article
Journal Article
BMC Genomics, ISSN 1471-2164, 06/2012, Volume 13, Issue 1, pp. 274 - 274
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2013, Volume 72, Issue 1, pp. 159 - 165
Adjuvant chemotherapy is gaining an increasing role in resectable gastric cancer. Customizing chemotherapy on the basis of chemosensitivity may improve... 
Medicine & Public Health | ERCC1 | Oncology | Cancer Research | Gastric | Adjuvant | Pharmacology/Toxicology | Cisplatin | GASTROESOPHAGEAL CANCER | RANDOMIZED-TRIALS | THYMIDYLATE SYNTHASE | CURATIVE RESECTION | DRUG-RESISTANCE | 5-FLUOROURACIL-BASED SYSTEMIC CHEMOTHERAPY | GROWTH-FACTOR RECEPTOR | LUNG-CANCER | ONCOLOGY | PHARMACOLOGY & PHARMACY | EXPRESSION | THYMIDINE PHOSPHORYLASE | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Stomach Neoplasms - metabolism | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Stomach - metabolism | Antineoplastic Agents - administration & dosage | Endonucleases - metabolism | Neoplasm Proteins - metabolism | Stomach - surgery | Cisplatin - administration & dosage | DNA-Binding Proteins - metabolism | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Adult | Female | Retrospective Studies | Chemotherapy, Adjuvant | Stomach - drug effects | Stomach - pathology | Europe | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Cisplatin - therapeutic use | Survival Analysis | Aged | Neoplasm Staging | Stomach Neoplasms - surgery | Adenocarcinoma - surgery | Cohort Studies | Immunohistochemistry | Medical research | Prognosis | Patient outcomes | Antineoplastic agents | Stomach cancer | Antimitotic agents | Cancer patients | Chemotherapy | Analysis | Medicine, Experimental | Tumor proteins | Cancer | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2011, Volume 17, Issue 14, pp. 4901 - 4914
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2008, Volume 26, Issue 22, pp. 3695 - 3701
Journal Article